Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reck

Showing results (1181-1190 of 1,518) with videos related to

Pageof 152
Sort By:
BMC Public Health|April 16, 2020
Evaluation of a computer-assisted multi-professional intervention to address lifestyle-related risk factors for overweight and obesity in expecting mothers and their infants: protocol for an effectiveness-implementation hybrid studyAdrienne Alayli, Franziska Krebs, Laura Lorenz, et al.
American Journal of Clinical Dermatology|July 15, 2025
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable StudyAndrew Alexis, Ali Moiin, Jill Waibel, et al.
Journal of Orofacial Orthopedics = Fortschritte Der Kieferorthopadie : Organ/Official Journal Deutsche Gesellschaft Fur Kieferorthopadie|April 26, 2024
Quality of orthodontic care-A multicenter cohort study in a German convenience sample : Part 2: Cross-sectional patient-reported outcomes after orthodontic treatmentIsabelle Graf, Niko Christian Bock, Theodosia Bartzela, et al.
Annals of Surgical Oncology|March 12, 2025
Money Matters: The Effect of Income on Postsurgical Outcomes in Stage IA Non-small Cell Lung CancerJ Asher Jenkins, Mohamed R Aly, Juan Maria Farina, et al.
Journal of Pediatric Surgery|November 13, 2019
Factors predicting the need for vaginal replacement at the time of primary reconstruction of a cloacal malformationAlejandra Vilanova-Sanchez, Devin R Halleran, Carlos A Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2012
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerKatsuyuki Hotta, Etsuji Suzuki, Massimo Di Maio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancerS Novello, B Besse, E Felip, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2014
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancerSilvia Novello, Rolf Kaiser, Anders Mellemgaard, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
Pageof 152

Showing results (1181-1190 of 1,518) with videos related to

Sort By:
Pageof 152
BMC Public Health|April 16, 2020
Evaluation of a computer-assisted multi-professional intervention to address lifestyle-related risk factors for overweight and obesity in expecting mothers and their infants: protocol for an effectiveness-implementation hybrid studyAdrienne Alayli, Franziska Krebs, Laura Lorenz, et al.
American Journal of Clinical Dermatology|July 15, 2025
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable StudyAndrew Alexis, Ali Moiin, Jill Waibel, et al.
Journal of Orofacial Orthopedics = Fortschritte Der Kieferorthopadie : Organ/Official Journal Deutsche Gesellschaft Fur Kieferorthopadie|April 26, 2024
Quality of orthodontic care-A multicenter cohort study in a German convenience sample : Part 2: Cross-sectional patient-reported outcomes after orthodontic treatmentIsabelle Graf, Niko Christian Bock, Theodosia Bartzela, et al.
Annals of Surgical Oncology|March 12, 2025
Money Matters: The Effect of Income on Postsurgical Outcomes in Stage IA Non-small Cell Lung CancerJ Asher Jenkins, Mohamed R Aly, Juan Maria Farina, et al.
Journal of Pediatric Surgery|November 13, 2019
Factors predicting the need for vaginal replacement at the time of primary reconstruction of a cloacal malformationAlejandra Vilanova-Sanchez, Devin R Halleran, Carlos A Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2012
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerKatsuyuki Hotta, Etsuji Suzuki, Massimo Di Maio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancerS Novello, B Besse, E Felip, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2014
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancerSilvia Novello, Rolf Kaiser, Anders Mellemgaard, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2Nicolai D Raig, Katherine J Surridge, Marta Sanz-Murillo, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
Pageof 152